Evolent Health (EVH) Financials

$10.73 +0.78 (+7.84%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$10.42 -0.31 (-2.90%)

As of 05/2/2025 07:56 PM Eastern

Annual Income Statements for Evolent Health

This table shows Evolent Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-25	332	-160	-61	-53	-302	-334	-38	-19	-142	-93
Consolidated Net Income / (Loss)	-25	320	-227	-70	-54	-306	-334	-38	-19	-113	-62
Net Income / (Loss) Continuing Operations	-25	320	-227	-70	-54	-307	-328	-30	-19	-113	-62
Total Pre-Tax Income	-25	343	-238	-76	-54	-330	-331	-30	-62	-202	-63
Total Operating Income	0.00	-43	-237	-73	-47	-309	-263	-42	3.64	-71	-40
Total Gross Profit	0.00	97	254	435	627	687	925	250	317	460	367
Total Revenue	0.00	97	254	435	627	687	925	908	1,352	1,964	2,555
Operating Revenue	0.00	97	254	435	627	687	925	908	1,352	1,964	2,555
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	658	1,035	1,503	2,187
Operating Cost of Revenue	-	-	-	-	-	-	-	658	1,035	1,503	2,187
Total Operating Expenses	0.00	140	492	508	674	996	1,187	293	313	532	408
Selling, General & Admin Expense	0.00	75	161	206	235	236	210	219	269	358	263
Depreciation Expense	0.00	7.17	17	32	45	60	61	60	67	123	118
Other Operating Expenses / (Income)	0.00	57	155	269	399	513	697	-	0.00	0.00	19
Impairment Charge	0.00	0.00	161	0.00	0.00	200	215	0.00	0.00	24	2.59
Other Special Charges / (Income)	0.00	0.00	-2.09	0.40	-4.10	-14	4.56	13	-24	26	4.91
Total Other Income / (Expense), net	-25	386	-0.12	-3.74	-6.78	-21	-68	13	-66	-131	-23
Interest Expense	0.00	0.00	0.25	3.64	5.48	15	33	47	26	75	25
Interest & Investment Income	-25	-28	0.13	-0.10	-1.30	-6.06	-34	60	5.94	6.55	2.10
Other Income / (Expense), net	0.00	414	-	-	-	-0.49	-0.12	-0.15	-46	-63	0.07
Income Tax Expense	0.00	23	-11	-6.64	0.04	-23	-2.37	0.48	-43	-89	-1.41
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	1.61	-6.07	-7.32	-0.46	0.00	0.00
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	0.00	0.00	29	32
Basic Earnings per Share	($13.46)	$13.14	($3.55)	($0.94)	($0.68)	($3.67)	($3.94)	($0.44)	($0.20)	($1.28)	($0.81)
Weighted Average Basic Shares Outstanding	2.31M	25.13M	45.03M	64.35M	77.34M	82.36M	84.93M	86.07M	93.70M	111.25M	114.68M
Diluted Earnings per Share	($13.46)	$6.93	($3.55)	($0.94)	($0.68)	($3.67)	($3.94)	($0.44)	($0.20)	($1.28)	($0.81)
Weighted Average Diluted Shares Outstanding	2.31M	46.14M	45.03M	64.35M	77.34M	82.36M	84.93M	86.07M	93.70M	111.25M	114.68M
Weighted Average Basic & Diluted Shares Outstanding	1.90M	25.30M	45.03M	64.35M	77.34M	82.36M	84.93M	90.83M	111.05M	115.43M	116.59M

This table shows Evolent Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	2.12	-11	-26	-41	-33	-41	-25	-6.38	-31	-31
Consolidated Net Income / (Loss)	2.12	-11	-20	-34	-25	-33	-17	1.60	-23	-23
Net Income / (Loss) Continuing Operations	2.12	-11	-20	-34	-25	-33	-17	1.60	-23	-23
Total Pre-Tax Income	-43	-10	-88	-35	-31	-48	-17	1.36	-24	-24
Total Operating Income	13	-1.88	-10	-22	-18	-21	-13	7.79	-16	-19
Total Gross Profit	86	83	117	117	124	102	104	107	81	76
Total Revenue	353	382	428	469	511	556	640	647	621	647
Operating Revenue	353	382	428	469	511	556	640	647	621	647
Total Cost of Revenue	267	299	310	352	387	454	536	540	541	571
Operating Cost of Revenue	267	299	310	352	387	454	536	540	541	571
Total Operating Expenses	73	85	128	139	142	123	118	99	97	94
Selling, General & Admin Expense	69	83	90	90	97	81	79	69	67	48
Depreciation Expense	17	20	29	32	32	30	30	30	30	29
Other Special Charges / (Income)	-13	-18	8.57	-7.82	13	12	8.91	0.00	0.20	-4.20
Total Other Income / (Expense), net	-56	-8.35	-78	-14	-13	-27	-3.31	-6.43	-7.49	-5.33
Interest Expense	15	6.43	13	14	15	33	6.00	6.00	6.01	6.72
Interest & Investment Income	1.82	1.23	1.48	0.76	1.76	2.55	2.86	-0.33	-1.44	1.01
Other Income / (Expense), net	-43	-3.15	-66	-0.03	-0.08	3.98	-0.17	-0.11	-0.04	0.38
Income Tax Expense	-46	1.12	-68	-0.97	-5.55	-15	0.57	-0.24	-0.62	-1.12
Preferred Stock Dividends Declared	0.00	-	6.28	7.09	7.87	7.98	7.95	7.98	8.09	7.81
Basic Earnings per Share	$0.02	($0.11)	($0.24)	($0.37)	($0.30)	($0.37)	($0.22)	($0.06)	($0.27)	($0.26)
Weighted Average Basic Shares Outstanding	95.29M	93.70M	107.78M	111.28M	112.28M	111.25M	114.14M	114.69M	114.86M	114.68M
Diluted Earnings per Share	$0.02	($0.11)	($0.24)	($0.37)	($0.30)	($0.37)	($0.22)	($0.06)	($0.27)	($0.26)
Weighted Average Diluted Shares Outstanding	99.31M	93.70M	107.78M	111.28M	112.28M	111.25M	114.14M	114.69M	114.86M	114.68M
Weighted Average Basic & Diluted Shares Outstanding	101.19M	111.05M	112.67M	113.24M	114.96M	115.43M	116.21M	116.29M	116.56M	116.59M

This table details how cash moves in and out of Evolent Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	0.00	152	18	125	93	-260	233	-6.64	-140	8.30	-45
Net Cash From Operating Activities	0.00	-18	-36	-28	-21	-43	-16	39	-12	143	19
Net Cash From Continuing Operating Activities	0.00	-18	-36	-28	-21	-43	-16	39	-12	143	19
Net Income / (Loss) Continuing Operations	-25	320	-227	-70	-54	-306	-334	-38	-19	-113	-62
Consolidated Net Income / (Loss)	-25	320	-227	-70	-54	-306	-334	-38	-19	-113	-62
Depreciation Expense	0.00	7.17	17	32	45	61	61	60	67	123	118
Amortization Expense	-	0.00	0.00	0.91	5.16	15	36	31	25	15	8.35
Non-Cash Adjustments To Reconcile Net Income	25	-371	180	11	-3.93	231	179	-40	-37	143	8.80
Changes in Operating Assets and Liabilities, net	0.00	26	-6.23	-2.90	-12	-44	42	25	-48	-25	-55
Net Cash From Investing Activities	0.00	-44	-97	-12	-160	-182	261	-16	-259	-416	-63
Net Cash From Continuing Investing Activities	0.00	-44	-97	-12	-160	-182	261	-16	-259	-416	-63
Purchase of Property, Plant & Equipment	0.00	-6.52	-16	-28	-40	-36	-29	-25	-38	-29	-25
Acquisitions	0.00	-	-	-3.69	-130	-8.58	-0.30	-49	-248	-388	-31
Purchase of Investments	0.00	-54	-7.95	-4.93	-19	-93	-10	-3.00	0.00	0.00	-7.32
Divestitures	0.00	13	0.00	0.00	0.50	0.00	157	46	22	0.58	0.00
Sale and/or Maturity of Investments	0.00	4.00	9.38	44	8.29	2.58	143	15	5.55	0.87	0.01
Net Cash From Financing Activities	0.00	214	150	166	274	-36	-12	-30	132	281	-0.57
Net Cash From Continuing Financing Activities	0.00	214	150	166	274	-36	-12	-30	132	281	-0.57
Repayment of Debt	-	0.00	-	-4.20	0.00	0.00	-17	-99	0.00	-464	0.00
Payment of Dividends	-	-	-	-	0.00	0.00	-20	-1.30	-15	-19	-20
Issuance of Debt	0.00	6.29	149	0.00	167	63	30	0.00	220	647	59
Issuance of Preferred Equity	-	-	-	-	-	-	-	0.00	0.00	168	0.00
Other Financing Activities, net	0.00	0.15	1.62	2.81	107	-98	-5.32	71	-73	-51	-39
Effect of Exchange Rate Changes	-	-	-	-	-	0.03	0.07	-0.05	-0.66	-0.08	-0.23

This table details how cash moves in and out of Evolent Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-86	20	-23	16	17	-1.04	10	-96	-10	51
Net Cash From Operating Activities	-3.47	36	-7.97	0.65	61	89	4.91	21	19	-26
Net Cash From Continuing Operating Activities	-3.47	36	-7.97	0.65	61	89	4.91	21	19	-26
Net Income / (Loss) Continuing Operations	2.12	-11	-20	-34	-25	-33	-17	1.60	-23	-23
Consolidated Net Income / (Loss)	2.12	-11	-20	-34	-25	-33	-17	1.60	-23	-23
Depreciation Expense	17	20	29	32	32	30	30	30	30	29
Amortization Expense	2.27	8.83	3.20	4.39	3.33	3.84	2.09	2.00	2.17	2.09
Non-Cash Adjustments To Reconcile Net Income	-25	12	31	-6.41	25	93	1.72	16	-35	26
Changes in Operating Assets and Liabilities, net	-0.38	6.21	-51	4.87	25	-3.83	-11	-28	45	-61
Net Cash From Investing Activities	-255	-4.46	-395	-8.35	-6.15	-6.05	-9.73	-14	-20	-20
Net Cash From Continuing Investing Activities	-255	-4.46	-395	-8.35	-6.15	-6.05	-9.73	-14	-20	-20
Purchase of Property, Plant & Equipment	-9.87	-11	-9.06	-6.85	-6.79	-6.05	-5.35	-7.11	-6.29	-6.15
Acquisitions	-236	-3.09	-387	-1.52	-	-	-1.39	-4.56	-11	-14
Purchase of Investments	-	-	0.00	-	-	-	-3.00	-1.88	-2.44	-0.00
Net Cash From Financing Activities	173	-11	380	23	-37	-84	15	-103	-9.01	97
Net Cash From Continuing Financing Activities	173	-11	380	23	-37	-84	15	-103	-9.01	97
Payment of Dividends	-	-	-3.65	-4.88	-5.10	-5.16	-5.08	-5.07	-5.13	-4.81
Issuance of Debt	220	-	256	-0.27	-	391	-0.53	-	-	59
Other Financing Activities, net	-47	-11	-3.45	28	-22	-54	20	-98	-3.87	43
Effect of Exchange Rate Changes	-0.24	-0.05	0.05	-0.00	-0.11	-0.02	-0.04	-0.02	-0.03	-0.14

This table presents Evolent Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	37	1,016	1,200	1,313	1,722	1,498	1,372	1,419	1,817	2,680	2,544
Total Current Assets	0.00	184	265	378	488	229	548	524	478	684	607
Cash & Equivalents	0.00	146	135	238	228	101	319	266	188	193	104
Restricted Cash	0.00	4.70	34	62	155	20	14	76	14	14	59
Accounts Receivable	0.00	20	41	49	80	76	124	131	255	447	415
Prepaid Expenses	0.00	4.21	11	8.40	23	28	56	51	21	30	29
Plant, Property, & Equipment, net	0.00	13	31	51	74	85	86	81	88	78	73
Total Noncurrent Assets	37	818	904	884	1,161	1,184	738	814	1,251	1,918	1,864
Long-Term Investments	37	46	8.16	4.82	22	148	13	18	17	22	24
Goodwill	0.00	609	627	628	768	572	349	426	723	1,117	1,137
Intangible Assets	0.00	163	259	241	335	308	265	280	443	752	680
Other Noncurrent Operating Assets	-	0.00	10	9.33	35	156	90	90	69	28	23
Total Liabilities & Shareholders' Equity	37	1,016	1,200	1,313	1,722	1,498	1,372	1,419	1,817	2,680	2,544
Total Liabilities	0.00	81	288	266	533	569	752	726	958	1,434	1,353
Total Current Liabilities	0.00	60	132	133	269	193	403	445	433	674	716
Short-Term Debt	-	-	-	-	-	0.00	27	-	-	0.00	171
Accounts Payable	0.00	17	44	43	147	37	32	96	57	48	96
Accrued Expenses	0.00	6.05	29	30	49	33	73	107	111	150	66
Current Deferred Revenue	0.00	15	20	25	-	20	10	12	5.76	5.98	2.51
Current Employee Benefit Liabilities	0.00	22	38	35	25	35	47	52	52	56	34
Other Current Liabilities	-	-	-	0.00	48	67	186	178	207	414	345
Total Noncurrent Liabilities	0.00	21	156	134	264	376	349	280	524	760	637
Long-Term Debt	-	0.00	120	121	221	294	263	216	413	597	491
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	21	21	2.44	25	1.94	0.68	1.40	4.74	13	11
Other Noncurrent Operating Liabilities	0.00	0.11	15	9.86	17	81	85	63	107	150	136
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	39	-	-	-	-	-	-	-	0.00	178	190
Total Equity & Noncontrolling Interests	-2.07	935	912	1,046	1,189	929	620	694	859	1,068	1,001
Total Preferred & Common Equity	-2.07	649	703	1,011	1,144	922	620	694	859	1,068	1,001
Total Common Equity	-2.07	649	702	1,010	1,144	922	619	694	859	1,068	1,001
Common Stock	24	343	555	924	1,094	1,175	1,229	1,342	1,488	1,809	1,805
Retained Earnings	-26	307	147	86	50	-252	-589	-627	-606	-719	-781
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	-0.18	-0.23	-0.28	-0.36	-1.18	-1.26	-1.75
Other Equity Adjustments	-	-	-	-	-	-	-	-21	-21	-21	-21

This table presents Evolent Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,759	2,589	2,647	2,670	2,644	2,475	2,502
Total Current Assets	394	476	577	639	669	521	544
Cash & Equivalents	157	158	143	185	165	101	97
Restricted Cash	25	22	47	23	52	20	16
Accounts Receivable	188	263	345	394	428	374	408
Prepaid Expenses	24	34	41	37	25	26	23
Plant, Property, & Equipment, net	95	89	84	80	76	75	74
Total Noncurrent Assets	1,271	2,025	1,987	1,951	1,898	1,879	1,884
Long-Term Investments	18	17	22	22	25	25	23
Goodwill	723	1,118	1,118	1,118	1,117	1,117	1,137
Intangible Assets	451	826	802	778	731	711	697
Other Noncurrent Operating Assets	78	64	45	34	26	26	26
Total Liabilities & Shareholders' Equity	1,759	2,589	2,647	2,670	2,644	2,475	2,502
Total Liabilities	903	1,297	1,381	1,398	1,414	1,237	1,276
Total Current Liabilities	382	458	541	615	659	483	524
Accounts Payable	62	51	77	52	77	39	50
Accrued Expenses	132	170	167	194	165	85	120
Current Deferred Revenue	7.52	7.07	6.95	5.76	6.14	4.56	2.62
Current Employee Benefit Liabilities	38	28	38	50	29	31	32
Other Current Liabilities	143	202	252	313	381	324	319
Total Noncurrent Liabilities	521	839	840	783	755	754	752
Long-Term Debt	412	632	633	600	598	599	600
Noncurrent Deferred & Payable Income Tax Liabilities	3.61	148	146	27	13	13	12
Other Noncurrent Operating Liabilities	105	59	61	156	144	142	141
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	171	173	176	181	184	187
Total Equity & Noncontrolling Interests	856	1,122	1,093	1,096	1,048	1,054	1,039
Total Preferred & Common Equity	856	1,122	1,093	1,096	1,048	1,054	1,039
Total Common Equity	856	1,122	1,093	1,096	1,048	1,054	1,039
Common Stock	1,473	1,770	1,776	1,804	1,807	1,811	1,819
Retained Earnings	-595	-626	-660	-686	-736	-735	-758
Accumulated Other Comprehensive Income / (Loss)	-1.04	-1.12	-1.11	-1.27	-1.31	-1.36	-1.37
Other Equity Adjustments	-21	-21	-21	-21	0.18	-21	-21

This table displays calculated financial ratios and metrics derived from Evolent Health's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	0.00%	162.38%	71.11%	44.17%	9.58%	34.57%	-1.80%	48.91%	45.26%	30.09%
EBITDA Growth	100.00%	0.00%	-158.20%	82.04%	105.54%	-10,741.50%	29.08%	129.34%	3.57%	-91.18%	1,845.84%
EBIT Growth	100.00%	0.00%	-163.97%	69.32%	34.82%	-551.59%	15.00%	83.82%	0.72%	-216.53%	69.78%
NOPAT Growth	100.00%	0.00%	-315.14%	69.32%	34.82%	-550.56%	14.90%	83.86%	108.59%	-2,055.27%	43.15%
Net Income Growth	-226.09%	1,366.79%	-170.91%	69.24%	22.33%	-463.89%	-9.38%	88.75%	49.03%	-489.86%	45.49%
EPS Growth	-1,459.60%	151.49%	-151.23%	73.52%	27.66%	-439.71%	-7.36%	88.83%	54.55%	-540.00%	36.72%
Operating Cash Flow Growth	100.00%	0.00%	-92.28%	21.27%	26.14%	-106.50%	61.95%	338.81%	-129.82%	1,334.16%	-86.84%
Free Cash Flow Firm Growth	0.00%	0.00%	67.65%	58.92%	-72.49%	7.22%	241.55%	-118.05%	-1,100.61%	-22.06%	86.95%
Invested Capital Growth	0.00%	0.00%	11.31%	6.31%	16.58%	-5.25%	-43.62%	2.25%	91.79%	53.39%	3.19%
Revenue Q/Q Growth	0.00%	0.00%	19.77%	6.28%	14.49%	-30.94%	64.12%	0.20%	11.01%	9.70%	3.67%
EBITDA Q/Q Growth	0.00%	0.00%	-8.00%	34.12%	125.66%	-306.94%	54.83%	-27.75%	35.54%	-62.86%	-3.25%
EBIT Q/Q Growth	0.00%	0.00%	-9.04%	17.66%	9.35%	-136.88%	42.71%	-63.42%	14.66%	-10.16%	-2.14%
NOPAT Q/Q Growth	0.00%	0.00%	-9.04%	17.66%	9.35%	-136.51%	42.74%	-65.18%	154.41%	-37.64%	6.37%
Net Income Q/Q Growth	0.00%	0.00%	-8.07%	14.05%	-7.43%	-146.78%	35.69%	17.82%	-42.36%	-24.25%	14.69%
EPS Q/Q Growth	0.00%	0.00%	-113.86%	4.08%	-11.48%	-147.97%	35.94%	22.81%	-33.33%	-25.49%	11.96%
Operating Cash Flow Q/Q Growth	0.00%	-51.91%	-74.79%	49.62%	-299.49%	47.22%	-265.34%	195.06%	-159.53%	60.39%	-86.04%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	70.21%	-184.43%	38.40%	-1.98%	33.15%	2.61%	-0.16%	-4.71%
Invested Capital Q/Q Growth	0.00%	0.00%	37.15%	-1.16%	11.98%	-11.12%	4.44%	-1.72%	-1.48%	-1.73%	-1.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	27.58%	23.42%	23.45%	14.38%
EBITDA Margin	0.00%	390.52%	-86.63%	-9.09%	0.35%	-33.96%	-17.90%	5.35%	3.72%	0.23%	3.38%
Operating Margin	0.00%	-44.36%	-93.40%	-16.75%	-7.57%	-44.95%	-28.43%	-4.67%	0.27%	-3.63%	-1.58%
EBIT Margin	0.00%	383.12%	-93.40%	-16.75%	-7.57%	-45.02%	-28.44%	-4.69%	-3.13%	-6.81%	-1.58%
Profit (Net Income) Margin	0.00%	330.12%	-89.22%	-16.04%	-8.64%	-44.47%	-36.15%	-4.14%	-1.42%	-5.76%	-2.41%
Tax Burden Percent	100.00%	93.16%	95.47%	91.31%	100.07%	92.60%	101.12%	126.17%	30.87%	55.85%	97.76%
Interest Burden Percent	0.00%	92.49%	100.05%	104.89%	114.05%	106.66%	125.70%	70.03%	146.92%	151.35%	155.96%
Effective Tax Rate	0.00%	6.84%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-10.99%	-21.59%	-6.10%	-3.56%	-22.10%	-24.71%	-5.47%	0.32%	-3.74%	-1.73%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-306.82%	17.84%	7.06%	7.81%	88.74%	479.37%	1.49%	-88.98%	-26.22%	-9.62%
Return on Net Nonoperating Assets (RNNOA)	0.00%	76.81%	-2.97%	-1.03%	-1.29%	-6.75%	-18.45%	-0.26%	-2.79%	-7.00%	-3.33%
Return on Equity (ROE)	-67.86%	65.82%	-24.56%	-7.12%	-4.85%	-28.85%	-43.17%	-5.73%	-2.47%	-10.74%	-5.06%
Cash Return on Invested Capital (CROIC)	0.00%	-210.99%	-32.30%	-12.21%	-18.87%	-16.70%	31.07%	-7.69%	-62.60%	-45.88%	-4.87%
Operating Return on Assets (OROA)	0.00%	70.51%	-21.43%	-5.80%	-3.13%	-19.21%	-18.33%	-3.05%	-2.61%	-5.95%	-1.55%
Return on Assets (ROA)	0.00%	60.76%	-20.47%	-5.55%	-3.57%	-18.98%	-23.29%	-2.69%	-1.18%	-5.03%	-2.36%
Return on Common Equity (ROCE)	3.78%	43.84%	-17.97%	-6.23%	-4.67%	-28.14%	-42.96%	-5.72%	-2.47%	-9.83%	-4.29%
Return on Equity Simple (ROE_SIMPLE)	1,219.61%	49.25%	-32.28%	-6.90%	-4.74%	-33.13%	-53.95%	-5.42%	-2.23%	-10.59%	-6.15%
Net Operating Profit after Tax (NOPAT)	0.00	-40	-166	-51	-33	-216	-184	-30	2.55	-50	-28
NOPAT Margin	0.00%	-41.32%	-65.38%	-11.72%	-5.30%	-31.47%	-19.90%	-3.27%	0.19%	-2.54%	-1.11%
Net Nonoperating Expense Percent (NNEP)	-135.72%	295.83%	-39.43%	-13.16%	-11.37%	-110.84%	-504.08%	-6.96%	89.30%	22.49%	7.89%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	0.20%	-2.99%	-1.70%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	72.42%	76.58%	76.55%	85.62%
SG&A Expenses to Revenue	0.00%	77.71%	63.22%	47.29%	37.54%	34.41%	22.76%	24.18%	19.92%	18.23%	10.30%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	144.36%	193.40%	116.71%	107.55%	144.95%	128.43%	32.25%	23.15%	27.07%	15.96%
Earnings before Interest and Taxes (EBIT)	0.00	371	-237	-73	-47	-309	-263	-43	-42	-134	-40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.00	378	-220	-40	2.19	-233	-166	49	50	4.44	86
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	1.10	1.43	0.94	1.43	0.83	2.22	3.57	3.31	3.56	1.31
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	6.76	40.34	18.30	291.32	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	7.38	3.95	2.19	2.62	1.11	1.49	2.72	2.10	1.93	0.51
Price to Earnings (P/E)	0.00	2.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	46.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.09	1.37	0.93	1.49	0.84	2.46	4.24	2.88	2.69	1.19
Enterprise Value to Revenue (EV/Rev)	0.00	8.19	4.38	1.84	2.39	1.16	1.43	2.57	2.24	2.21	0.77
Enterprise Value to EBITDA (EV/EBITDA)	0.00	2.10	0.00	0.00	684.72	0.00	0.00	47.96	60.33	979.54	22.90
Enterprise Value to EBIT (EV/EBIT)	0.00	2.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,190.40	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	60.11	0.00	30.47	105.32
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	5.70	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.13	0.12	0.19	0.32	0.47	0.31	0.48	0.48	0.56
Long-Term Debt to Equity	0.00	0.00	0.13	0.12	0.19	0.32	0.43	0.31	0.48	0.48	0.41
Financial Leverage	-1.00	-0.25	-0.17	-0.15	-0.16	-0.08	-0.04	-0.17	0.03	0.27	0.35
Leverage Ratio	1.00	1.08	1.20	1.28	1.36	1.52	1.85	2.13	2.08	2.14	2.14
Compound Leverage Factor	0.00	1.00	1.20	1.35	1.55	1.62	2.33	1.49	3.06	3.23	3.34
Debt to Total Capital	0.00%	0.00%	11.65%	10.40%	15.67%	24.02%	31.87%	23.72%	32.46%	32.39%	35.72%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.92%	0.00%	0.00%	0.00%	9.25%
Long-Term Debt to Total Capital	0.00%	0.00%	11.65%	10.40%	15.67%	24.02%	28.95%	23.72%	32.46%	32.39%	26.47%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	105.56%	30.52%	20.30%	3.03%	3.23%	0.55%	0.00%	0.00%	0.00%	9.68%	10.26%
Common Equity to Total Capital	-5.57%	69.48%	67.98%	86.50%	81.10%	75.44%	68.03%	76.28%	67.54%	57.93%	54.02%
Debt to EBITDA	0.00	0.00	-0.55	-3.07	100.79	-1.26	-1.75	4.44	8.21	134.62	7.67
Net Debt to EBITDA	0.00	0.00	0.46	4.66	-84.08	-0.10	0.34	-2.98	3.84	83.13	5.50
Long-Term Debt to EBITDA	0.00	0.00	-0.55	-3.07	100.79	-1.26	-1.59	4.44	8.21	134.62	5.68
Debt to NOPAT	0.00	0.00	-0.72	-2.38	-6.65	-1.36	-1.58	-7.26	161.99	-11.98	-23.36
Net Debt to NOPAT	0.00	0.00	0.61	3.61	5.55	-0.11	0.31	4.87	75.84	-7.40	-16.76
Long-Term Debt to NOPAT	0.00	0.00	-0.72	-2.38	-6.65	-1.36	-1.43	-7.26	161.99	-11.98	-17.31
Altman Z-Score	0.00	7.17	1.96	2.61	2.31	0.38	0.66	2.03	2.01	1.79	1.05
Noncontrolling Interest Sharing Ratio	105.57%	33.39%	26.83%	12.58%	3.66%	2.47%	0.49%	0.07%	0.00%	8.47%	15.12%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.10	2.01	2.85	1.81	1.19	1.36	1.18	1.10	1.01	0.85
Quick Ratio	0.00	2.95	1.66	2.32	1.15	0.93	1.10	0.89	1.02	0.95	0.73
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-769	-249	-102	-176	-163	231	-42	-501	-612	-80
Operating Cash Flow to CapEx	0.00%	-283.47%	-228.71%	-100.40%	-52.21%	-120.01%	-55.05%	155.09%	-30.12%	496.02%	75.38%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-1,006.50	-28.09	-32.12	-11.23	6.99	-0.89	-19.46	-8.14	-3.23
Operating Cash Flow to Interest Expense	0.00	0.00	-143.77	-7.69	-3.77	-2.93	-0.49	0.83	-0.45	1.90	0.76
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-206.62	-15.35	-10.98	-5.37	-1.38	0.29	-1.94	1.51	-0.25
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.18	0.23	0.35	0.41	0.43	0.64	0.65	0.84	0.87	0.98
Accounts Receivable Turnover	0.00	0.00	8.33	9.71	9.71	8.82	9.26	7.13	7.02	5.60	5.93
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	11.56	10.60	10.07	8.65	10.79	10.83	15.98	23.65	33.76
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.27	13.51	28.52	30.32
Days Sales Outstanding (DSO)	0.00	0.00	43.81	37.59	37.59	41.40	39.42	51.19	52.01	65.18	61.54
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	35.54	27.01	12.80	12.04
Cash Conversion Cycle (CCC)	0.00	0.00	43.81	37.59	37.59	41.40	39.42	15.65	25.00	52.39	49.50
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	729	811	862	1,005	952	537	549	1,053	1,615	1,666
Invested Capital Turnover	0.00	0.27	0.33	0.52	0.67	0.70	1.24	1.67	1.69	1.47	1.56
Increase / (Decrease) in Invested Capital	0.00	729	82	51	143	-53	-415	12	504	562	52
Enterprise Value (EV)	0.00	794	1,114	802	1,502	796	1,318	2,329	3,035	4,344	1,976
Market Capitalization	0.00	714	1,005	951	1,640	766	1,375	2,474	2,841	3,797	1,311
Book Value per Share	($0.90)	$11.01	$10.33	$13.06	$13.91	$10.90	$7.21	$7.76	$8.49	$9.29	$8.59
Tangible Book Value per Share	($0.90)	($2.08)	($2.70)	$1.82	$0.49	$0.49	$0.06	($0.14)	($3.03)	($6.97)	($7.00)
Total Capital	37	935	1,032	1,168	1,410	1,223	910	909	1,272	1,843	1,853
Total Debt	0.00	0.00	120	121	221	294	290	216	413	597	662
Total Long-Term Debt	0.00	0.00	120	121	221	294	263	216	413	597	491
Net Debt	-37	-206	-101	-184	-184	23	-57	-145	193	369	475
Capital Expenditures (CapEx)	0.00	6.52	16	28	40	36	29	25	38	29	25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-35	-80	-55	-164	-87	-162	-263	-158	-197	-100
Debt-free Net Working Capital (DFNWC)	0.00	125	133	245	219	36	171	78	45	9.43	63
Net Working Capital (NWC)	0.00	125	133	245	219	36	144	78	45	9.43	-108
Net Nonoperating Expense (NNE)	25	-360	61	19	21	89	150	7.91	22	63	33
Net Nonoperating Obligations (NNO)	-37	-206	-101	-184	-184	23	-83	-145	193	369	475
Total Depreciation and Amortization (D&A)	0.00	7.17	17	33	50	76	97	91	93	138	127
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-36.04%	-31.59%	-12.73%	-26.22%	-12.64%	-17.57%	-29.02%	-11.69%	-10.04%	-3.93%
Debt-free Net Working Capital to Revenue	0.00%	128.98%	52.33%	56.44%	34.86%	5.24%	18.48%	8.64%	3.30%	0.48%	2.47%
Net Working Capital to Revenue	0.00%	128.98%	52.33%	56.44%	34.86%	5.24%	15.61%	8.64%	3.30%	0.48%	-4.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($13.46)	$13.14	($3.55)	($0.94)	($0.68)	($3.67)	($3.94)	($0.44)	($0.20)	($1.28)	($0.81)
Adjusted Weighted Average Basic Shares Outstanding	2.31M	25.13M	45.03M	64.35M	82.57M	84.72M	86.09M	86.07M	93.70M	111.25M	114.68M
Adjusted Diluted Earnings per Share	($13.46)	$6.93	($3.55)	($0.94)	($0.68)	($3.67)	($3.94)	($0.44)	($0.20)	($1.28)	($0.81)
Adjusted Weighted Average Diluted Shares Outstanding	2.31M	46.14M	45.03M	64.35M	82.57M	84.72M	86.09M	86.07M	93.70M	111.25M	114.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($3.55)	$0.00	($0.68)	($3.67)	($3.94)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.90M	60.08M	67.96M	77.44M	77.34M	82.36M	84.93M	90.83M	111.05M	115.43M	116.59M
Normalized Net Operating Profit after Tax (NOPAT)	0.00	-40	-55	-51	-36	-86	-30	-20	-14	-15	-23
Normalized NOPAT Margin	0.00%	-41.32%	-21.73%	-11.66%	-5.76%	-12.50%	-3.27%	-2.25%	-1.03%	-0.75%	-0.90%
Pre Tax Income Margin	0.00%	354.35%	-93.45%	-17.57%	-8.64%	-48.02%	-35.75%	-3.28%	-4.59%	-10.31%	-2.47%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-961.21	-20.03	-8.66	-21.26	-7.94	-0.91	-1.64	-1.78	-1.63
NOPAT to Interest Expense	0.00	0.00	-672.85	-14.02	-6.06	-14.86	-5.56	-0.63	0.10	-0.66	-1.15
EBIT Less CapEx to Interest Expense	0.00	0.00	-1,024.07	-27.69	-15.87	-23.70	-8.83	-1.44	-3.13	-2.16	-2.64
NOPAT Less CapEx to Interest Expense	0.00	0.00	-735.71	-21.68	-13.27	-17.30	-6.45	-1.17	-1.39	-1.04	-2.15
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.98%	-3.46%	-77.67%	-16.63%	-32.59%
Augmented Payout Ratio	0.00%	0.43%	0.00%	0.00%	0.00%	0.00%	-5.98%	-3.46%	-77.67%	-16.63%	-32.59%

This table displays calculated financial ratios and metrics derived from Evolent Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	58.49%	53.98%	43.98%	46.63%	44.93%	45.40%	49.56%	37.94%	21.60%	16.27%
EBITDA Growth	-174.94%	127.00%	-279.18%	16.49%	264.02%	-31.83%	140.68%	164.97%	-12.18%	-18.05%
EBIT Growth	-357.02%	59.05%	-2,829.73%	-398.02%	40.47%	-245.22%	82.32%	135.58%	9.46%	-4.88%
NOPAT Growth	296.79%	90.83%	-270.09%	-365.53%	-238.51%	-1,036.85%	-29.49%	160.62%	9.31%	12.90%
Net Income Growth	116.28%	-100.97%	-273.50%	-648.10%	-1,292.84%	-194.40%	13.52%	104.65%	8.64%	31.75%
EPS Growth	113.33%	-83.33%	-300.00%	-640.00%	-1,600.00%	-236.36%	8.33%	83.78%	10.00%	29.73%
Operating Cash Flow Growth	-107.80%	-46.45%	86.12%	-95.21%	1,844.12%	150.40%	161.56%	3,174.77%	-69.15%	-129.35%
Free Cash Flow Firm Growth	-920.47%	-1,812.89%	-1,105.61%	-6,711.20%	-17.23%	-14.22%	112.06%	100.53%	90.23%	88.82%
Invested Capital Growth	91.33%	91.79%	175.54%	175.70%	53.79%	53.39%	-8.28%	0.20%	2.80%	3.19%
Revenue Q/Q Growth	10.20%	8.47%	11.83%	9.69%	8.93%	8.81%	15.03%	1.17%	-3.98%	4.05%
EBITDA Q/Q Growth	-184.31%	318.25%	-287.81%	133.71%	18.71%	-9.29%	12.09%	119.53%	-60.66%	-15.35%
EBIT Q/Q Growth	-597.97%	83.38%	-1,425.72%	71.87%	16.57%	3.59%	21.84%	156.60%	-312.30%	-11.67%
NOPAT Q/Q Growth	379.54%	-114.50%	-451.38%	-108.29%	16.83%	-19.02%	37.19%	197.51%	-224.42%	-14.31%
Net Income Q/Q Growth	146.27%	-634.57%	-76.07%	-71.77%	26.22%	-31.93%	48.28%	109.24%	-1,549.69%	1.45%
EPS Q/Q Growth	140.00%	-650.00%	-118.18%	-54.17%	18.92%	-23.33%	40.54%	72.73%	-350.00%	3.70%
Operating Cash Flow Q/Q Growth	-125.40%	1,128.67%	-122.34%	108.20%	9,153.98%	47.69%	-94.51%	336.28%	-12.83%	-240.50%
Free Cash Flow Firm Q/Q Growth	-3,029.57%	-0.84%	-119.42%	1.64%	46.14%	1.75%	123.18%	-95.64%	-1,084.21%	-12.46%
Invested Capital Q/Q Growth	74.61%	-1.48%	64.19%	-2.39%	-2.60%	-1.73%	-1.82%	6.63%	-0.08%	-1.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	24.38%	21.72%	27.41%	24.98%	24.35%	18.28%	16.28%	16.51%	12.99%	11.71%
EBITDA Margin	-3.06%	6.17%	-10.35%	3.18%	3.47%	2.89%	2.82%	6.11%	2.50%	2.04%
Operating Margin	3.67%	-0.49%	-2.42%	-4.60%	-3.51%	-3.84%	-2.10%	1.20%	-2.62%	-2.88%
EBIT Margin	-8.58%	-1.32%	-17.95%	-4.60%	-3.53%	-3.12%	-2.12%	1.19%	-2.62%	-2.82%
Profit (Net Income) Margin	0.60%	-2.97%	-4.67%	-7.32%	-4.96%	-6.01%	-2.70%	0.25%	-3.72%	-3.53%
Tax Burden Percent	-4.89%	110.97%	22.66%	97.25%	82.02%	69.51%	103.38%	117.53%	97.39%	95.31%
Interest Burden Percent	143.38%	203.28%	114.87%	163.44%	171.38%	276.76%	123.14%	17.68%	145.64%	131.34%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-17.53%	0.00%	0.00%
Return on Invested Capital (ROIC)	3.85%	-0.58%	-2.13%	-4.57%	-3.24%	-3.96%	-1.93%	1.97%	-2.71%	-3.14%
ROIC Less NNEP Spread (ROIC-NNEP)	-4.65%	-41.85%	-7.76%	-13.72%	-7.62%	-10.53%	-3.92%	0.24%	-5.52%	-5.46%
Return on Net Nonoperating Assets (RNNOA)	-0.52%	-1.31%	-1.84%	-3.07%	-2.09%	-2.81%	-1.23%	0.08%	-1.85%	-1.89%
Return on Equity (ROE)	3.33%	-1.89%	-3.98%	-7.64%	-5.33%	-6.77%	-3.16%	2.06%	-4.56%	-5.02%
Cash Return on Invested Capital (CROIC)	-63.27%	-62.60%	-93.72%	-94.80%	-45.06%	-45.88%	5.50%	-2.06%	-4.58%	-4.87%
Operating Return on Assets (OROA)	-6.94%	-1.10%	-13.55%	-3.80%	-2.85%	-2.73%	-1.76%	1.09%	-2.50%	-2.76%
Return on Assets (ROA)	0.49%	-2.48%	-3.53%	-6.04%	-4.01%	-5.25%	-2.25%	0.23%	-3.55%	-3.45%
Return on Common Equity (ROCE)	3.33%	-1.89%	-3.62%	-6.93%	-4.89%	-6.19%	-2.72%	1.76%	-3.90%	-4.26%
Return on Equity Simple (ROE_SIMPLE)	-1.57%	0.00%	-3.01%	-5.81%	-8.30%	0.00%	-10.53%	-7.06%	-6.95%	0.00%
Net Operating Profit after Tax (NOPAT)	9.07	-1.31	-7.25	-15	-13	-15	-9.39	9.15	-11	-13
NOPAT Margin	2.57%	-0.34%	-1.69%	-3.22%	-2.46%	-2.69%	-1.47%	1.41%	-1.83%	-2.01%
Net Nonoperating Expense Percent (NNEP)	8.50%	41.27%	5.63%	9.15%	4.37%	6.57%	1.99%	1.73%	2.81%	2.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.10%	-	-	-	-0.90%	-	-	-	-0.78%
Cost of Revenue to Revenue	75.62%	78.28%	72.59%	75.02%	75.65%	81.72%	83.72%	83.49%	87.01%	88.29%
SG&A Expenses to Revenue	19.43%	21.67%	20.98%	19.27%	18.90%	14.64%	12.37%	10.69%	10.79%	7.38%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.71%	22.21%	29.83%	29.58%	27.86%	22.12%	18.37%	15.31%	15.60%	14.59%
Earnings before Interest and Taxes (EBIT)	-30	-5.03	-77	-22	-18	-17	-14	7.68	-16	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	24	-44	15	18	16	18	40	16	13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.85	3.31	3.21	3.12	2.81	3.56	3.60	2.11	3.17	1.31
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.70	2.10	2.43	2.09	1.72	1.93	1.73	0.94	1.33	0.51
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.28	2.88	2.44	2.38	2.21	2.69	2.72	1.69	2.33	1.19
Enterprise Value to Revenue (EV/Rev)	2.88	2.24	2.84	2.46	2.03	2.21	1.98	1.21	1.60	0.77
Enterprise Value to EBITDA (EV/EBITDA)	94.48	60.33	0.00	0.00	304.09	979.54	64.54	31.29	44.16	22.90
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	1,190.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	180.65	0.00	111.05	160.92	40.84	30.47	27.70	16.22	29.32	105.32
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	47.27	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.48	0.48	0.49	0.50	0.47	0.48	0.49	0.48	0.49	0.56
Long-Term Debt to Equity	0.48	0.48	0.49	0.50	0.47	0.48	0.49	0.48	0.49	0.41
Financial Leverage	0.11	0.03	0.24	0.22	0.27	0.27	0.31	0.35	0.33	0.35
Leverage Ratio	2.06	2.08	2.06	2.10	2.08	2.14	2.08	2.05	2.07	2.14
Compound Leverage Factor	2.95	4.24	2.37	3.44	3.57	5.91	2.56	0.36	3.02	2.82
Debt to Total Capital	32.51%	32.46%	32.85%	33.33%	32.09%	32.39%	32.72%	32.60%	32.85%	35.72%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.05%	0.00%	0.00%	0.00%	0.00%	9.25%
Long-Term Debt to Total Capital	32.51%	32.46%	32.85%	33.33%	32.04%	32.39%	32.72%	32.60%	32.85%	26.47%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	8.87%	9.10%	9.38%	9.68%	9.92%	10.03%	10.25%	10.26%
Common Equity to Total Capital	67.49%	67.54%	58.28%	57.57%	58.53%	57.93%	57.36%	57.37%	56.90%	54.02%
Debt to EBITDA	11.11	8.21	-33.82	-38.17	50.33	134.62	8.96	6.55	6.72	7.67
Net Debt to EBITDA	5.72	3.84	-23.33	-25.40	31.12	83.13	5.34	4.95	5.20	5.50
Long-Term Debt to EBITDA	11.11	8.21	-33.82	-38.17	50.25	134.62	8.96	6.55	6.72	5.68
Debt to NOPAT	-88.02	161.99	-230.72	-43.37	-16.59	-11.98	-11.50	-19.05	-19.81	-23.36
Net Debt to NOPAT	-45.33	75.84	-159.17	-28.86	-10.26	-7.40	-6.85	-14.39	-15.31	-16.76
Long-Term Debt to NOPAT	-88.02	161.99	-230.72	-43.37	-16.57	-11.98	-11.50	-19.05	-19.81	-17.31
Altman Z-Score	2.36	2.08	1.81	1.74	1.62	1.93	2.02	1.64	2.10	1.08
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	9.01%	9.20%	8.25%	8.47%	13.95%	14.26%	14.53%	15.12%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.03	1.10	1.04	1.07	1.04	1.01	1.02	1.08	1.04	0.85
Quick Ratio	0.90	1.02	0.92	0.90	0.94	0.95	0.90	0.98	0.96	0.73
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-501	-505	-1,108	-1,090	-587	-577	134	5.83	-57	-65
Operating Cash Flow to CapEx	-35.14%	332.26%	-88.06%	9.55%	890.93%	1,476.88%	91.81%	301.39%	296.87%	-426.45%
Free Cash Flow to Firm to Interest Expense	-33.52	-78.58	-85.96	-75.41	-40.19	-17.35	22.30	0.97	-9.55	-9.60
Operating Cash Flow to Interest Expense	-0.23	5.55	-0.62	0.05	4.14	2.69	0.82	3.57	3.11	-3.90
Operating Cash Flow Less CapEx to Interest Expense	-0.89	3.88	-1.32	-0.43	3.68	2.51	-0.07	2.39	2.06	-4.82
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.81	0.84	0.75	0.83	0.81	0.87	0.83	0.92	0.95	0.98
Accounts Receivable Turnover	6.71	7.02	6.71	7.04	6.15	5.60	6.30	6.55	6.14	5.93
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	13.82	15.98	17.29	18.53	20.51	23.65	26.43	29.64	32.04	33.76
Accounts Payable Turnover	27.97	13.51	19.58	14.16	23.73	28.52	26.93	33.05	40.66	30.32
Days Sales Outstanding (DSO)	54.37	52.01	54.41	51.87	59.32	65.18	57.92	55.75	59.41	61.54
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	13.05	27.01	18.64	25.78	15.38	12.80	13.55	11.04	8.98	12.04
Cash Conversion Cycle (CCC)	41.32	25.00	35.77	26.09	43.93	52.39	44.36	44.70	50.43	49.50
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,069	1,053	1,729	1,687	1,643	1,615	1,585	1,691	1,689	1,666
Invested Capital Turnover	1.50	1.69	1.26	1.42	1.32	1.47	1.31	1.39	1.48	1.56
Increase / (Decrease) in Invested Capital	510	504	1,101	1,075	575	562	-143	3.32	46	52
Enterprise Value (EV)	3,506	3,035	4,210	4,008	3,631	4,344	4,307	2,859	3,939	1,976
Market Capitalization	3,294	2,841	3,604	3,414	3,084	3,797	3,770	2,222	3,289	1,311
Book Value per Share	$9.34	$8.49	$10.10	$9.70	$9.68	$9.29	$9.18	$9.07	$8.93	$8.59
Tangible Book Value per Share	($3.47)	($3.03)	($7.40)	($7.33)	($7.06)	($6.97)	($7.01)	($6.66)	($6.84)	($7.00)
Total Capital	1,269	1,272	1,925	1,899	1,873	1,843	1,827	1,837	1,826	1,853
Total Debt	412	413	632	633	601	597	598	599	600	662
Total Long-Term Debt	412	413	632	633	600	597	598	599	600	491
Net Debt	212	193	436	421	372	369	356	452	463	475
Capital Expenditures (CapEx)	9.87	11	9.06	6.85	6.79	6.05	5.35	7.11	6.29	6.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-170	-158	-161	-154	-183	-197	-207	-84	-93	-100
Debt-free Net Working Capital (DFNWC)	12	45	18	36	24	9.43	10	38	20	63
Net Working Capital (NWC)	12	45	18	36	24	9.43	10	38	20	-108
Net Nonoperating Expense (NNE)	6.94	10	13	19	13	18	7.89	7.56	12	9.78
Net Nonoperating Obligations (NNO)	212	193	436	421	372	369	356	452	463	475
Total Depreciation and Amortization (D&A)	19	29	32	37	36	33	32	32	32	31
Debt-free, Cash-free Net Working Capital to Revenue	-13.96%	-11.69%	-10.87%	-9.45%	-10.24%	-10.04%	-9.49%	-3.56%	-3.76%	-3.93%
Debt-free Net Working Capital to Revenue	0.96%	3.30%	1.24%	2.19%	1.37%	0.48%	0.47%	1.60%	0.82%	2.47%
Net Working Capital to Revenue	0.96%	3.30%	1.24%	2.19%	1.31%	0.48%	0.47%	1.60%	0.82%	-4.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.02	($0.11)	($0.24)	($0.37)	($0.30)	($0.37)	($0.22)	($0.06)	($0.27)	($0.26)
Adjusted Weighted Average Basic Shares Outstanding	95.29M	93.70M	107.78M	111.28M	112.28M	111.25M	114.14M	114.69M	114.86M	114.68M
Adjusted Diluted Earnings per Share	$0.02	($0.11)	($0.24)	($0.37)	($0.30)	($0.37)	($0.22)	($0.06)	($0.27)	($0.26)
Adjusted Weighted Average Diluted Shares Outstanding	99.31M	93.70M	107.78M	111.28M	112.28M	111.25M	114.14M	114.69M	114.86M	114.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	101.19M	111.05M	112.67M	113.24M	114.96M	115.43M	116.21M	116.29M	116.56M	116.59M
Normalized Net Operating Profit after Tax (NOPAT)	0.18	-14	-1.25	-3.73	-3.18	-6.58	-3.15	5.45	-11	-16
Normalized NOPAT Margin	0.05%	-3.58%	-0.29%	-0.79%	-0.62%	-1.18%	-0.49%	0.84%	-1.81%	-2.47%
Pre Tax Income Margin	-12.31%	-2.67%	-20.62%	-7.52%	-6.04%	-8.64%	-2.61%	0.21%	-3.82%	-3.70%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.02	-0.78	-5.95	-1.49	-1.23	-0.52	-2.26	1.28	-2.71	-2.71
NOPAT to Interest Expense	0.61	-0.20	-0.56	-1.04	-0.86	-0.45	-1.57	1.53	-1.89	-1.94
EBIT Less CapEx to Interest Expense	-2.69	-2.45	-6.65	-1.97	-1.70	-0.70	-3.16	0.10	-3.76	-3.63
NOPAT Less CapEx to Interest Expense	-0.05	-1.88	-1.26	-1.52	-1.32	-0.63	-2.46	0.34	-2.94	-2.85
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-110.56%	-77.67%	-51.59%	-13.43%	-14.98%	-16.63%	-18.33%	-27.42%	-28.30%	-32.59%
Augmented Payout Ratio	-110.56%	-77.67%	-51.59%	-13.43%	-14.98%	-16.63%	-18.33%	-27.42%	-28.30%	-32.59%

Frequently Asked Questions About Evolent Health's Financials

When does Evolent Health's financial year end?

According to the most recent income statement we have on file, Evolent Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Evolent Health's net income changed over the last 10 years?

Evolent Health's net income appears to be on an upward trend, with a most recent value of -$61.62 million in 2024, rising from -$25.25 million in 2014. The previous period was -$113.04 million in 2023. See where experts think Evolent Health is headed by visiting Evolent Health's forecast page.

What is Evolent Health's operating income?

Evolent Health's total operating income in 2024 was -$40.49 million, based on the following breakdown:

Total Gross Profit: $367.35 million
Total Operating Expenses: $407.84 million

How has Evolent Health revenue changed over the last 10 years?

Over the last 10 years, Evolent Health's total revenue changed from $0.00 in 2014 to $2.55 billion in 2024, a change of 255,474,100,000.0%.

How much debt does Evolent Health have?

Evolent Health's total liabilities were at $1.35 billion at the end of 2024, a 5.7% decrease from 2023, and a 135,297,900,000.0% increase since 2014.

How much cash does Evolent Health have?

In the past 10 years, Evolent Health's cash and equivalents has ranged from $0.00 in 2014 to $319.00 million in 2020, and is currently $104.20 million as of their latest financial filing in 2024.

How has Evolent Health's book value per share changed over the last 10 years?

Over the last 10 years, Evolent Health's book value per share changed from -0.90 in 2014 to 8.59 in 2024, a change of -1,058.8%.

Related Companies

This page (NYSE:EVH) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolent Health (EVH) Financials

Frequently Asked Questions About Evolent Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolent Health (EVH) Financials

Annual Income Statements for Evolent Health

Quarterly Income Statements for Evolent Health

Annual Cash Flow Statements for Evolent Health

Quarterly Cash Flow Statements for Evolent Health

Annual Balance Sheets for Evolent Health

Quarterly Balance Sheets for Evolent Health

Annual Metrics and Ratios for Evolent Health

Quarterly Metrics and Ratios for Evolent Health

Frequently Asked Questions About Evolent Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools